Skip to main content
SpringerLink
Log in

Leflunomide, a reversible inhibitor of pyrimidine biosynthesis?

  • VI. Lymphocyte activation/immunoregulation
  • Published:
Inflammation Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Bartlett RR, Campion G, Musikic P, Zielinski T, Schorlemmer HU. Leflunomide: A Novel Immunomodulating Drug. In: Lewis AL, Furst DE, editors. Nonsteroidal Anti-Inflammatory Drugs, Mechanisms and Clinical Uses.

  2. Küchle CCA, Thoenes GH, Langer KH, Schorlemmer HU, Bartlett RR, Schleyerbach R. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant Proc 1991;23:1083–6.

    PubMed  Google Scholar 

  3. Wright JR, Kearns H, McDonald AS. Leflunomide and Cyclosporine-A Prolongs Fish-to-Mouse Islet Xenograft Survival in Balb/c Mice. Transplant Proc 1994;26:1310.

    PubMed  Google Scholar 

  4. Zielinski T, Müller HJ, Bartlett RR. of Leflunomide (HWA 486) on Expression of Lymphocyte Activation Markers. Agents Actions 1993;38:C80–2.

    PubMed  Google Scholar 

  5. Cohen A, Barankiewicz J, Lederman HM, Gelland EW. Purine and Pyrimidine Metabolism in Human T Lymphocytes. Regulation of Deoxyribonucleotide Metabolism. J Biol Chem 1983;258:12334–40.

    PubMed  Google Scholar 

  6. Carson DA, Kaye J, Seegmiller JE. Lymphospecific Toxicity in Adenosine Deaminase Deficiency and Purine Nucleoside Phosphorylase Deficiency: possible role of Nucleoside Kinase(s). Proc Natl Acad Sci 1977;74:5677–81.

    PubMed  Google Scholar 

  7. Weber G. Biochemical Strategy of Cancer Cells and the Design of Chemotherapy: GHA Clowes Memorial Lecture. Cancer Res 1983;43:3466–92. 2nd ed. New York: Dekker, 1994:349–66.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, University of Mainz, D-55101, Mainz, Germany

    T. Zielinski

  2. Department of Immunopharmacology, Hoechst AG, Werk Kalle-Albert, Wiesbaden, D-65174, Wiesbaden, Germany

    D. Zeitter, S. Müllner & R. R. Bartlett

Authors
  1. T. Zielinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Zeitter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Müllner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. R. Bartlett
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zielinski, T., Zeitter, D., Müllner, S. et al. Leflunomide, a reversible inhibitor of pyrimidine biosynthesis?. Inflamm Res 44 (Suppl 2), S207–S208 (1995). https://doi.org/10.1007/BF01778336

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01778336

Keywords

Search

Navigation